# A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

> **NCT04121286** · PHASE1 · COMPLETED · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Colorectal Cancer
- Pancreatic Ductal Carcinoma
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Breast Cancer
- Other Solid Tumors

## Interventions

- **DRUG:** JAB-3312

## Key facts

- **NCT ID:** NCT04121286
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-14
- **Primary completion:** 2022-06-17
- **Final completion:** 2022-06-17
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121286

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121286, "A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04121286. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*